“Selective JAK1 Inhibition Using Upadacitinib for the Management of Inflammatory Bowel Diseases: The Powerful Pill”. 2023. Canadian IBD Today 1 (S11): 2–11. https://doi.org/10.58931/cibdt.2023.1S1121.